Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.

NCT00174967 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00174967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00174967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2001
Completion date
July 31, 2001
Enrollment
153 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gout